Published in Women's Health Weekly, January 26th, 2006
Cash payments received to-date under the recently executed agreement for the exclusive marketing rights to Estrasorb in North America now total $10.0 million. Novavax will receive another $2.5 million from Esprit Pharma, Inc. upon the first anniversary of the agreement.
With the receipt of these funds announced today, the company's cash balance available for use in its 2006 business plan will be approximately $30 million as of year-end 2005.
Novavax, Inc. is a product...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly